- Johnson & Johnson (JNJ, Financial) is set to release its Q1 earnings on April 15, with an expected EPS of $2.58 on $21.57 billion in revenue.
- Guggenheim maintains a Neutral rating due to ITCI acquisition impacts, foreign exchange challenges, and litigation concerns.
- Analyst price targets suggest a potential upside of over 11% with an average target of $170.47.
Johnson & Johnson (JNJ) is gearing up for its much-anticipated Q1 earnings release on April 15. Wall Street is closely watching, with projected earnings per share (EPS) of $2.58 and revenue estimates hovering around $21.57 billion. Guggenheim recently made slight estimate adjustments, largely due to factors such as the ITCI acquisition and current foreign exchange pressures, while maintaining a Neutral stock rating amid ongoing litigation and exclusivity concerns.
Wall Street Analysts' Insights
A comprehensive analysis by 24 leading analysts indicates that Johnson & Johnson's average one-year price target is $170.47, ranging between a high of $185.00 and a low of $150.00. This suggests a noteworthy upside of 11.33% from its current trading price of $153.13. For an in-depth analysis, visit the Johnson & Johnson (JNJ, Financial) Forecast page.
Furthermore, the average brokerage recommendation compiled from 26 brokerage firms signals an "Outperform" status for JNJ, reflected in a score of 2.3 on a scale where 1 stands for Strong Buy and 5 for Sell.
GF Value Estimates and Upside Potential
According to GuruFocus, the projected GF Value for JNJ in the coming year stands at $187.89. This suggests a promising upside potential of 22.7% from its present price of $153.13. The GF Value represents an assessment of the fair trading value based on historical trading multiples, past business growth, and future performance predictions. To explore further details, navigate to the Johnson & Johnson (JNJ, Financial) Summary page.
